[SBIR/STTR Rosters]

The Oncological Sciences Small Business Activities Special Emphasis Panels [ONC Small Business SEPs] review small business applications including Small Business Innovation Research [SBIR] and Small Business Technology Transfer [STTR] grant applications concerned with basic, preclinical, and clinical studies in the oncological sciences.

  Cancer Drug Development and Therapeutics SBIR
[CDDT SBIR SEP: ONC (10)]

This Special Emphasis Panel reviews applications addressing the experimental therapy of neoplastic diseases in in vitro systems and in vivo model systems, including some early-stage, pilot clinical trials. The major emphasis of this study section is on the rational development of novel therapeutic strategies that have a significant potential for translation to the clinic.

Specific areas covered by the CDDT SBIR SEP include: 

• Development and evaluation of anti-cancer therapeutic agents in both in vitro and in vivo tumor model systems.
  
  
• Novel anti-cancer therapies and drug delivery mechanisms
  
  
• Identification and validation of new cancer relevant molecular targets for therapeutic intervention.
  
  
• Development of gene therapy with viral or non-viral based delivery in animal models.
  
  
• Experimental cancer therapeutics
  
  
• Mechanisms of drug resistance and strategies to circumvent resistance.
  
  
• Natural compounds that modulate signal transudation, cell cycle, angiogenic or apoptotic pathways.

 The CDDT SBIR SEP has the following shared interests outside the ONC IRG:

• With the Biological Chemistry and Macromolecular Biophysics IRG [BCMB]: Studies related to drug synthesis and protein structures, lipids/biopolymers synthesis, and biochemical activity of low molecular weight compounds of natural or synthetic origins could be assigned to BCMB.

Cancer Diagnostics and Treatments SBIR
[CDT SBIR SEP: ONC (12)]

This Special Emphasis Panel reviews grant applications related to diagnosis and treatment of cancer. This includes biomarkers as prognosticators of cancer, bioimmunotherapies of cancer, and novel approaches to treating cancer.

 Specific areas covered by the CDT SBIR SEP include:

• Discovery of biomarkers for cancer detection, diagnosis and prognosis
  
  
• Pre-clinical and clinical validation of cancer biomarkers
  
  
• Novel assays, instrumentation and analysis algorithm for cancer screening, and metastasis and survival prediction
  
  
• Basic, pre-clinical and clinical testing for tumor genetic and epigenetic variations
  
  
• Cancer related proteomics
  
  
• Pre-clinical and clinical modeling of carcinogenesis, tumor development, metastasis, prevention and treatment
  
  
• Evaluation of immunotherapeutic strategies in preclinical models, and translational studies leading to pilot and/or phase-1 clinical trials
  
  
• Development and testing of tumor vaccines: including nucleotide-based vaccines, peptide-based vaccines, cell-based vaccines, and vaccines using ex-vivo modified cells

The CDT SBIR SEP has the following shared interests outside the ONC IRG: 

•  With the Genes, Genomes and Genetics IRG [GGG]: In general, studies in genetics, genomics, and nucleic acid technology, including molecular assays, bioinstrumentation, bioinformatics and educational tools could be assigned to GGG. Translational studies that are directly linked to cancer could be assigned to the CDT SBIR SEP.
  
  
• With the Bioengineering Sciences and Technologies IRG [BST]: In general, basic studies directed toward developing gene and drug delivery systems, microscopic imaging, modeling and analysis of biological systems, biodata management and analysis, instrumentation and systems development, and biomaterial and biointerfaces could be assigned to BST. Translational studies of the applications of these results to cancer could be assigned to the CDT SBIR SEP.

• With the Risk, Prevention and Health Behavior IRG [RPHB]: Studies focused on social, behavioral, and technological interventions designed to reduce the risk of cancer, improve cancer treatment and management could be assigned to RPHB. Studies related to cancer therapeutics and prevention could be assigned to the CDT SBIR SEP.

• With the Immunology IRG [IMM]: In general, studies that include basic immune responses, immunoassays, regulations of immune reaction could be assigned to IMM. Translational studies that include testing of immunodetection and immunotherapeutic approaches to cancer could be assigned to the CDT SBIR SEP.
   
• With the Endocrinology, Metabolism, Nutrition, and Reproductive Sciences IRG [EMNR]: Studies focused on metabolic functions, hormonal treatment, and dietary supplements could be assigned to EMNR. Studies related to dietary/natural products in prevention or treatment of cancer could generally be assigned to the CDT SBIR SEP.
  
   

Radiation Therapy and Biology SBIR
[RBT SBIR SEP: ONC (11)]

This Special Emphasis Panel reviews applications dealing with therapeutic interactions of ionizing radiation, radionuclides, electromagnetic radiation, and heat at the molecular, cellular, organ and patient levels.  This includes applications in which dose, dose rate, type of radiation, and quality of radiation are variables.

                    
 Specific areas covered by the RTB SBIR SEP:

• Radiation treatment and planning
  
  
• Dosimetry of brachytherapy
  
  
• Radiation physics and internal dosimetry
  
  
• Thermal ablation therapy
  
  
• Targeted radionuclide therapy
  
  
• Photodynamic Therapy (PDT) Heavy ion or Neutron Capture Therapy
  
  
• Technology and outcome analysis methodologies related to radiation treatment and planning
  
  
• Imaging and image analysis as it relates to radiation treatment and assessment of response

The RTB SBIR SEP has the following shared interests outside the ONC IRG:

• With the Surgical Sciences, Biomedical Imaging, and Bioengineering IRG [SBIB]:  In general, studies of radiotherapy for the treatment of cancer could be assigned to the RBT SBIR SEP. Development and testing of imaging devices and nuclear medicine technologies for cancer diagnosis could be assigned to SBIB.